<DOC>
	<DOC>NCT00105196</DOC>
	<brief_summary>The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective eight week trial of the same assigned open-label marketed antidepressant therapy.</brief_summary>
	<brief_title>A Study of Aripiprazole in Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Men and women, 1865 years old who have experienced single or recurrent, nonpsychotic episodes of Major Depressive Disorder, with the current episode of minimally 8 weeks in duration. Treatment history of an inadequate response to at least one and no more than three adequate antidepressant trials.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Single or recurrent</keyword>
	<keyword>non-psychotic episode of Major Depressive Disorder</keyword>
</DOC>